Company Profile
Year Established :
2005
Total Assets(USD) :
Less than 500,000
Total Number of Staff :
Less than 10 persons
Other Competitive Advantages :
Most of our products comply with such pharmacopoeia standards as USP, EP, JP, CP, with GMP certificate and DMF(in CTD).
Business Type :
,Manufacturer
Annual Turnover(USD) :
7,000,000 to 7,999,999
Main Sales Markets :
North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Main Product Categorise :
Active Pharmaceutical Ingredients,Intermediates,Fine Chemicals
Product Range :
Glipizide; Flunarizine dihydrochloride; Loxoprofen sodium; 4-(2-Aminoethyl)benzene sulfonamide; etc
Dijia Pharmaceutical, established in 2013,is a national high-tech enterprise integrating research and development, production and sales of APIs, pharmaceutical intermediates and biological products.
Dijia Pharmaceutical is always committed to the development, production and marketing of APIs, pharmaceutical intermediates and biological products. The product profile of the company is reasonable. According to the action position and working mechanism of formulation, it mainly includes musculoskeletal system, cardiovascular system, nervous system, digestive tract and metabolism, respiratory system and other fields. At the same time, the company is also engaged in BIM, BMPPA and other medical intermediates business and a small number of biological products. Some products have achieved PMDA certification in Japan, MFDS certification in South Korea, and CEP certification in the European Union. Products are exported to Japan, South Korea, India and other overseas market.
The company focuses on customer needs, with more product types, reliable product quality, years of technical accumulation and good customer service, to win recognition of customers, and work together with customers for double win development.
As a national high-tech enterprise, the company adheres to the business philosophy of "R&D dominate the future, innovation determines success or failure", and attaches great importance to the improvement of comprehensive scientific research strength and investment in product research and development.
The company based on independent research and development, continuous implementation of technological innovation, always adheres to the market-oriented, customer demand as the goal over the years, closely follows the international and domestic advanced technology development trend, and constantly optimizes research and development resources. It has formed three core technology platforms, namely "separation and purification technology platform", "biological enzyme catalysis technology platform" and "green synthesis technology platform", and successively launched a number of self-developed products with high technical content and added value.